



Republic of the Philippines  
Department of Health  
**OFFICE OF THE SECRETARY**

**DEPARTMENT MEMORANDUM**

No. 2015- 0233

**TO :** ALL REGIONAL OFFICE DIRECTORS AND SECRETARY OF HEALTH of AUTONOMOUS REGION OF MUSLIM MINDANAO

**SUBJECT :** GUIDE FOR 2015 NTP REPORTING OF TREATMENT OUTCOMES OF 2014 DRUG-SUSCEPTIBLE TB PATIENT COHORT

**DATE :** July 7, 2015

Recording and Reporting is an integral component of any health program of the Department of Health. It is a way of monitoring and evaluating the implementation status of a particular program, thus, strategies to keep the records and reports updated, available, complete and accurate have been incessantly being done. In 2013, the National Tuberculosis Control Program (NTP) revised the Manual of Procedures (MOP) and has brought changes in reporting data on case finding, diagnosis, registration, case holding and treatment.

Due to the ongoing transition from the old to the revised MOP, the NTP releases this guide specific for **Report 5a. Quarterly Report on the Treatment Outcome of Drug Susceptible TB (DSTB) Cases of 2014 cohort**. This guide is made to ensure: completeness, consistency and accuracy of the report. Also, this advisory is directed towards helping all implementers of the program from all levels and partner agencies to easily come up with the correct treatment outcome report patterned accordingly to the latest MOP with source or reference coming from their facility's old format of the DSTB register. With this, the specific guidelines on changes in the above-mentioned report are as follows:

1. The highlighted words in the attachment are registration groups of the previous MOP and these have been placed according to the corresponding registration group counterparts of the revised MOP. **This will only be applicable to reporting of 2014 cohort.**
2. New Smear Positive cases of 2014 cohort fall under Bacteriologically-confirmed while New Smear Negative and Extra-pulmonary cases of 2014 cohort are under Clinically-diagnosed.
3. All Relapse cases of 2014 cohort are to be categorized under Bacteriologically-confirmed cases.
4. All retreatment cases of 2014 cohort, such as Treatment After Failure, Return After Default, Other Negative and Other Positive, to exclude Relapse are to be counted under Previously Treated.
5. Trans-in patients will be noted in the Remarks.
6. Extra-pulmonary, Other Negative and Other Positive cases which are not previously reported in the previous MOP are to be included in the report as possible. Same provision goes for information needed in Table D.

7. All Report 5a to be submitted this year (Q1-Q4) shall be in this format. Those who have submitted their Q1 and Q2 2015 Reports are requested to resend their reports using this guide.

With this, the NTP Management Office hopes that you find the attached guide in this advisory helpful in composing your quality individual reports.

For further clarifications, please contact the designated Account Officer of NTP MO for your region or (02)310-5713 or [ntp.mne@gmail.com](mailto:ntp.mne@gmail.com).

By Authority of the Secretary of Health:



**VICENTE Y. BELIZARIO JR., MD, MTM&H**  
Undersecretary of Health  
Office for Technical Services

**Report 5a. Quarterly Report on Treatment Outcome of Drug-Susceptible TB Cases**  
(Data Source – Form 6a. Drug Susceptible TB Register)

RO: \_\_\_\_\_

Province/City: \_\_\_\_\_

Municipality: \_\_\_\_\_

DOTS Facility: \_\_\_\_\_

Total population of catchment area: \_\_\_\_\_

Cohort for cases registered in \_\_\_\_ Quarter of Year 2014

Date reported: \_\_\_\_\_

Prepared by: \_\_\_\_\_

Designation: \_\_\_\_\_

**For Province, City and Regional level:**

Total no. of DOTS facilities that submitted reports	
Total no. of DOTS Facility	

**A. Bacteriologically Confirmed New and Relapse TB Cases**

Total number of TB cases (2014)		Cured	Completed	Died	Failed	Lost to follow-up	Not Evaluated	TOTAL
	New (NSP)							
	Relapse (Relapse)							

Note: Exclude from the cohort the cases found to be drug resistant at anytime during treatment.  
Number of cases excluded from the cohort= \_\_\_\_\_

**B. Clinically Diagnosed New TB Cases**

Total number of TB cases (2014)		Completed	Died	Failed	Lost to follow-up	Not Evaluated	TOTAL
	New (NSN)						
	New (EP)						

Note: Exclude from the cohort the cases found to be drug resistant at anytime during treatment.  
Number of cases excluded from the cohort= \_\_\_\_\_

**C. Previously Treated Cases (except Relapse)**

Total number of TB cases (2014)	Other Retreatment	Cured	Completed	Died	Failed	Lost to follow-up	Not Evaluated	TOTAL
	TAF (Treatment Failure)							
	TALF (RAD)							
	Other Positive							
	Other Negative							

Note: Exclude from the cohort the cases found to be drug resistant at anytime during treatment.  
 Number of cases excluded from the cohort= \_\_\_\_\_

Trans-in Patients: \_\_\_\_\_

**D. Other Cohorts**

Total number of TB cases		Cured	Completed	Died	Failed	Lost to follow-up	Not Evaluated	TOTAL
	PLHIV cases (all registration groups)							
	Children Given IPT							

Note for PLHIV: Exclude from the cohort the cases found to be drug resistant at anytime during treatment.  
 Number of cases excluded from the cohort= \_\_\_\_\_